The workshop opened with a plenary talk by Dr. John Moore [1] from Weill Medical College of Cornell University, New York, NY, who reviewed mechanisms of viral escape from entry inhibitors. Such ...
Eighty-nine percent of patients with M184V or I remained suppressed and 11% did not have virologic data at the week 48 timepoint due to study drug discontinuation. The Food and Drug Administration ...
Patients with HIV who have suppressed viral loads and pre-existing resistance will be able to use bictegravir with this FDA approval. The FDA has approved an expanded indication for bictegravir ...
According to the study authors, bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) may be an option for simplification following viral suppression. Switching to coformulated ...
(RTTNews) - The U.S. Food and Drug Administration approved a new, expanded indication for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results